• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gilead Sciences (NQ:GILD)

    148.49 +2.26 (+1.55%)
    Streaming Delayed Price Updated: 9:35 AM EST, Feb 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Gilead Sciences

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    19 20 Next >
    News headline image
    Crossroads4Hope Kicks Off Its 25th Year of Caring with the Launch of Free Breast and Colorectal Cancer Resources for Patients and Families Nationwide
    Via PRLog
    News headline image
    The Commonwealth Club Honors Black History Month With Event Featuring Top Black Leaders in AI & Biopharma Discussing the Future of Healthcare
    Via Get News
    Topics Artificial Intelligence
    News headline image
    Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences to Present at Upcoming Investor Conference
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
    Issued on behalf of Oncolytics Biotech Inc. 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Foundation Commits Over $3 Million to Address Food Insecurity
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals
    November 10, 2025 -- During rehearsals leading up to the Induction Ceremony, GBK welcomed some of the world's biggest musicians from legendary icons to today's top superstars. 
    Via 24-7 Press Release
    News headline image
    Gilead Provides Update on Phase 3 ASCENT-07 Study
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences to Present at Upcoming Investor Conferences
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Announces Third Quarter 2025 Financial Results
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Jerry Pinkas Earns Certified Probate Specialist Designation, Elevating Compassionate Real Estate Expertise for South Carolina Families
    Via Get News
    News headline image
    Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
    From Gilead Sciences, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    19 20 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.